Literature DB >> 17993587

Murine models of pulmonary fibrosis.

Bethany B Moore1, Cory M Hogaboam.   

Abstract

Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of extracellular matrix proteins. The result is a progressive loss of normal lung architecture and impairment in gas exchange. Pertinent features of the human disease include temporal heterogeneity of the fibrotic lesions, progressive nature of the disease, development of fibrotic foci, and in some patients, a rapid worsening of symptoms known as an acute exacerbation. No current animal model recapitulates all of these cardinal manifestations of the human disease. However, investigations using murine models have led to the identification of many pathological cells and mediators that are believed to be important in human disease as well. In this review, we will summarize the characteristics, advantages, and disadvantages of many of the currently utilized murine models of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993587     DOI: 10.1152/ajplung.00313.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  306 in total

1.  miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis.

Authors:  Shanzhong Yang; Na Xie; Huachun Cui; Sami Banerjee; Edward Abraham; Victor J Thannickal; Gang Liu
Journal:  FASEB J       Date:  2012-06-01       Impact factor: 5.191

2.  Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling.

Authors:  Zachary Van Rheen; Cheryl Fattman; Shannon Domarski; Susan Majka; Dwight Klemm; Kurt R Stenmark; Eva Nozik-Grayck
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-10       Impact factor: 6.914

3.  Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.

Authors:  Rishi B Patel; Sainath R Kotha; Lynn A Sauers; Smitha Malireddy; Travis O Gurney; Niladri N Gupta; Terry S Elton; Ulysses J Magalang; Clay B Marsh; Boyd E Haley; Narasimham L Parinandi
Journal:  Toxicol Mech Methods       Date:  2012-06       Impact factor: 2.987

4.  Conditional depletion of airway progenitor cells induces peribronchiolar fibrosis.

Authors:  Anne-Karina T Perl; Dieter Riethmacher; Jeffrey A Whitsett
Journal:  Am J Respir Crit Care Med       Date:  2010-09-24       Impact factor: 21.405

5.  Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease.

Authors:  Vishwaraj Sontake; Shiva K Shanmukhappa; Betsy A DiPasquale; Geereddy B Reddy; Mario Medvedovic; William D Hardie; Eric S White; Satish K Madala
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

Review 6.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

7.  Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.

Authors:  Elizabeth F Redente; Rebecca C Keith; William Janssen; Peter M Henson; Luis A Ortiz; Gregory P Downey; Donna L Bratton; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

8.  Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Authors:  Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-28       Impact factor: 5.464

9.  Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds.

Authors:  Kevin K Kim; Thomas H Sisson; Jeffrey C Horowitz
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

10.  Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury.

Authors:  Melissa L Wilkinson; Elena Abramova; Changjiang Guo; James G Gow; Alexa Murray; Adolf Koudelka; Veronika Cechova; Bruce A Freeman; Andrew J Gow
Journal:  Toxicol Appl Pharmacol       Date:  2020-09-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.